


Amendments to the Claims

This Listing of the Claims will replace all prior versions, and listings, of claims in the application.

Listing of the Claims:

1.-22. (Cancelled).

23. (Currently Amended) A compound of formula I



wherein

each of R^0 , R^1 , R^2 , and R^3 independently is hydrogen, $-S(O)_{0-2}NR_{12}R_{13}$, $-S(O)_{0-2}R_{13}$, $-NR_{12}S(O)_{0-2}R_{13}$, and $-C(O)NR_{12}R_{13}$; wherein R_{12} is selected from hydrogen and C_{1-6} alkyl;

and R_{13} is selected from hydrogen, C_{1-6} alkyl and C_{3-12} cycloalkyl,

R^4 is hydrogen;

each of R^5 and R^6 independently is hydrogen, halogen, and

each of R^7 , R^8 , R^9 , and R^{10} independently is ethoxy, ethyl, propyl, t-butyl, trifluoromethyl, nitrile, cyclobutyloxy, 2,2,2-trifluoroethoxy, isobutyloxy, t-butyloxy, isopropoxy, methyl-amino-carbonyl, cyclopropyl-methoxy, dimethylamino-propyl-amino, methoxy-ethoxy, $-XR_{11}$, $-C(O)R_{11}$ and $-OXR_{11}$; wherein X is a bond, methylene or ethylene; R_{11} is selected from piperazinyl, piperidinyl, pyrrolidinyl, morpholino, azepanyl and 1,4-dioxo-8-aza-spiro[4.5]dec-8-yl; wherein R_{11} is optionally substituted by 1 to 3 radicals independently selected from methyl, isopropyl, acetyl, acetyl-methyl-amino, 3-dimethylamino-2,2-dimethyl-propylamino, ethyl-methyl-amino-ethoxy, diethyl-amino-ethoxy, amino-carbonyl, ethyl, 2-oxo-pyrrolidin-1-yl, pyrrolidinyl, pyrrolidinyl-methyl, piperidinyl optionally substituted with methyl or ethyl, morpholino, dimethylamino, dimethylamino-propyl-amino, methyl-amino and ethyl-amino,

wherein one of R^7 , R^8 and R^9 independently of each other can also be hydrogen;

A is C;
and salts thereof.

24. (Previously Presented) A compound of formula I according to claim 23, wherein each of R⁰ or R² independently is hydrogen;

R¹ is hydrogen;

R³ is selected from dimethyl-sulfamoyl, isobutyl-sulfamoyl, methyl-sulfamoyl, ethyl-sulfamoyl, propyl-sulfonyl, ethyl-amino-carbonyl, 1-ethyl-propyl-sulfamoyl, cyclopentyl-sulfamoyl, isopropyl-sulfamoyl, cyclohexyl-sulfonyl, cyclopropyl-methyl-sulfamoyl, cyclobutyl-sulfamoyl, isopropyl-sulfonyl.

25.-32. (Cancelled).

33. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 23, as active ingredient together with one or more pharmaceutically acceptable diluents or carriers.

34. (Previously Presented) A combination comprising a therapeutically effective amount of a compound according to claim 23 and one or more further known drug substances, said further drug substance being useful in the treatment of neoplastic diseases or immune system disorders.











35. (Currently Amended) A method for the treatment of breast tumor ~~neoplastic diseases and immune system disorders~~ in a subject in need thereof which comprises administering an effective amount of a compound according to claim 23.

36. (Previously Presented) A method for the treatment of a disease which responds to inhibition of focal adhesion kinase or/and IGF-1 Receptor which comprises administering an effective amount of a compound according to claim 23.

37. (Currently Amended) A method according to claim 36, wherein the disease to be treated is a breast tumor ~~proliferative disease~~.

38.-42. (Cancelled).

43. (Previously Presented) A compound of formula I according to claim 23, selected from



, or

32910B-US-PCT

